[1] [1] WHO．Coronavirus (COVID-19) dashboard [EB/OL]．[2024-11-05]．https：//covid19.who.int．

[2] [2] CHEN Y J，ZHAO X Y，ZHOU H，et al．Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses [J]．Nat Rev Immunol,2023,23 (3)：189-199．

[3] [3] KHOURY D S，CROMER D，REYNALDI A，et al．Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection [J]．Nat Med,2021,27 (7)：1205-1211．

[4] [4] CHIA W N,ZHU F,ONG S W X,et al．Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity：a longitudinal study [J]．Lancet Microbe，2021，2 (6)：e240-e249．

[5] [5] YANG S J,YU Y L,XU Y L,et al．Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure [J]．Lancet Infect Dis,2024,24 (2)：e70-e72．

[7] [7] WEIDNER L，GNSDORFER S，UNTERWEGER S，et al．Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays [J]．J Clin Virol,2020,129：104540．

[12] [12] PILZ S，CHAKERI A，IOANNIDIS J P，et al．SARS-CoV-2 reinfection risk in Austria [J]．Eur J Clin Invest，2021，51 (4)：e13520．

[13] [13] TOWNSEND J P，HASSLER H B，WANG Z，et al．The durability of immunity against reinfection by SARS-CoV-2：a comparative evolutionary study [J]．Lancet Microbe，2021，2 (12)：e666-e675．

[14] [14] CURLIN M E，BATES T A，GUZMAN G，et al．Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection [J]．Med，2022，3 (12)：827-837.e3．

[15] [15] WEI J，POUWELS K B，STOESSER N,et al．Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines [J]．Nat Med，2022，28(5)：1072-1082．

[16] [16] MLLER L，ANDRE M，MOSKORZ W，et al．Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination [J]．Clin Infect Dis，2021，73 (11)：2065-2072．

[17] [17] LEVIN E G，LUSTIG Y，COHEN C，et al．Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months [J]．N Engl J Med，2021，385 (24)：e84．

[18] [18] BLOMBERG B B，FRASCA D．Quantity，not quality，of antibody response decreased in the elderly [J]．J Clin Invest，2011，121(8)：2981-2983．

[19] [19] WEI J，MATTHEWS P C，STOESSER N，et al．Anti-spike antibody response to natural SARS-CoV-2 infection in the general population [J]．Nat Commun，2021，12 (1)：6250．

[20] [20] PAINTER M M，JOHNSTON T S，LUNDGREEN K A，et al．Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection [J]．Nat Immunol，2023，24 (10)：1711-1724．

[21] [21] CHOI S H，PARK J Y，KWEON O J，et al．Immune responses after vaccination with primary 2-dose ChAdOx1 plus a booster of BNT162b2 or vaccination with primary 2-dose BNT162b2 plus a booster of BNT162b2 and the occurrence of omicron breakthrough infection [J]．J Korean Med Sci，2023，38 (20)：e155.

[23] [23] MARKMANN A J，GIALLOUROU N，BHOWMIK D R，et al．Sex disparities and neutralizing-antibody durability to SARS-CoV-2 infection in convalescent individuals [J]．mSphere,2021,6 (4)：e0027521．

[24] [24] GUO L，ZHANG Q，GU X，et al．Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19：a longitudinal cohort study [J]．Lancet Microbe.2024，5 (1)：e24-e33．

[25] [25] KOHLER H．Novel vaccine concept based on back-boost effect in viral infection [J]．Vaccine，2015,33 (29)：3274-5．